QualityStar Receives 2024 Global Recognition Award for Outstanding Merit in Health & Wellness Supplements
NEW YORK, N.Y., Feb. 06, 2025 (GLOBE NEWSWIRE) -- QualityStar, a leading innovator of multi-benefit health supplements, has received a 2024 Global Recognition Award for its transformative contributions to health and nutrition science. The accolade recognizes the company's groundbreaking work in advancing bioavailability, nutrient synergy, and scientific research, setting new benchmarks in the industry.
The award highlights QualityStar's commitment to bridging the gap between traditional nutrition science and innovative approaches that prioritize health outcomes. By integrating advanced research methodologies and collaborating with global institutions, QualityStar has elevated industry standards and expanded access to effective nutritional solutions.
'This award is a testament to our dedication to advancing health through rigorous science and innovation,' said QualityStar's CEO. 'Our mission is to empower individuals with evidence-based tools that support optimal wellness while upholding the highest ethical and environmental standards.'
Pioneering Advances in Health and Nutrition
QualityStar's patented technologies have transformed how nutrients are combined and absorbed, leveraging state-of-the-art research to maximize health benefits. These innovations reflect the company's strategic partnerships with leading global institutions, driving progress in the broader health and nutrition sector.
The company operates in FDA-compliant, GMP-certified facilities in the United States, ensuring adherence to strict quality and safety protocols. Additionally, its commitment to sustainable practices has positioned QualityStar as a leader in ethical production and environmental stewardship.
'Our success stems from a relentless focus on quality, innovation, and a deep understanding of the needs of consumers worldwide,' the CEO added.
A Global Vision for Health and Wellness
Recognized by healthcare professionals across multiple continents, QualityStar continues to champion excellence in health-focused research and development. Its work has enhanced the accessibility of nutrition science, fostering global conversations about the importance of bioavailability, nutrient synergy, and sustainable practices in health innovation.
About QualityStarFounded by a team of renowned physicians and researchers, QualityStar has become a global leader in advancing health and nutrition. With a robust network of international collaborations and a foundation of ethical production practices, the company remains committed to fostering better health outcomes for individuals worldwide.
Contact Information:
Company Name: QualityStarContact Name: Emily MaxwelWebsite: www.qualitystarchoice.comEmail Address: hello@qualitystarchoice.comLocation: United States
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/caf4fe5a-0dce-4e8b-b4b8-f216e94546d3
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Quest Diagnostics to Offer FDA-Cleared Fujirebio Blood Test for Alzheimer's Disease
Test to be available for clinical and research use as soon as this summer, building on Quest's pioneering blood-based AD-Detect™ product line for assessing symptomatic patients SECAUCUS, N.J., July 9, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced it plans to offer laboratory testing based on the Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test from Fujirebio, a global leader in the field of high-quality IVD testing. Quest plans to make the test available to physicians and biopharmaceutical collaborators later this summer. The test is the first blood-based IVD test cleared by the U.S. Food and Drug Administration (FDA) to aid in identifying patients with amyloid pathology associated with Alzheimer's disease. It is designed to aid the clinical assessment of Alzheimer's disease in adult patients aged 50 years and older presenting at a specialized care setting with signs and symptoms of cognitive decline. Through its AD-Detect™ portfolio, Quest provides a suite of advanced lab-developed blood tests regulated under CLIA for assessing patients with cognitive impairment for Alzheimer's disease. The Fujirebio test offering extends this portfolio to include an FDA-cleared option for use in specialized care settings. "Our goal is to advance access to quality and innovative blood-based tests for Alzheimer's disease. Adding the Fujirebio test to our existing blood-based tests provides the many physicians we serve with another powerful option for assessing patients for Alzheimer's disease," said Kathleen Valentine, Vice President and General Manager, Neurology, Quest Diagnostics. "Blood-based testing can be less invasive and more convenient than traditional test methods. We are excited to leverage our expansive network of patient service centers to broaden access to the Fujirebio innovation to help more at-risk individuals gain access to the insights they need sooner." In a clinical study population of 499 patients, which closely mirrors US demographics, and when applying a dual cut point, the FDA-cleared test demonstrated a positive predictive value (PPV) of 92% and a negative predictive value (NPV) of 97%, with 20% of patients uncertain to have amyloid pathology, thus requiring further testing. Quest will showcase its complete line up of Alzheimer's and other neurological test innovations at this year's Alzheimer's Association International Conference (AAIC) in Toronto from July 27-31. "As brain health and Alzheimer's disease interventions continue to evolve, diagnosing patients earlier, when interventions can be most effective, is critical," said Michael Racke, MD, a board-certified neurologist and Medical Director of Neurology, Quest Diagnostics. "We are constantly looking for ways to help physicians and patients make the most informed decisions, and this new addition to our test menu will aid that goal." While amyloid PET imaging and cerebral spinal fluid testing are established methods for aiding the diagnosis of Alzheimer's disease, they are significantly more expensive, invasive and specialist-dependent than blood-based tests. With a physician's order, patients can conveniently provide a blood draw for testing for the Fujirebio test and any of the AD-Detect™ tests through Quest's network of patient sites. Quest maintains approximately 8,000 patient access points, including an extensive patient service center network of approximately 2,000 locations in the U.S., as well as phlebotomists in physician offices and mobile phlebotomy services. Specimens will be transported for testing to Quest's state-of-the-art laboratory in San Juan Capistrano, California. Nearly 7 million Americans have Alzheimer's, the most prevalent dementia, a number projected to reach 14 million by 2060. Approximately 12-18% of adults over the age of sixty are living with mild cognitive impairment, a potential sign of AD. Seventy-seven percent of physicians say new therapies will transform Alzheimer's into a chronic, manageable disease, and 94% of physicians say blood tests would be more cost effective for the healthcare system compared to more invasive methods of detection (e.g., lumbar puncture, imaging studies) according to a special report from Quest. Quest is committed to developing and offering innovative advanced diagnostics to aid in evaluating Alzheimer's disease and other brain diseases. For more information, visit About Quest DiagnosticsQuest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our nearly 55,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world. View original content to download multimedia: SOURCE Quest Diagnostics
Yahoo
26 minutes ago
- Yahoo
Quartus Capital Partners is Delighted to Announce the Final Closing of Quartus AI Fund LP with $50 Million Plus in Commitments
NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Quartus Capital Partners LLC is delighted to announce the final closing of Quartus AI Fund LP with $50 million plus in commitments. The firm attracted a diverse set of LPs, including endowments, foundations, RIAs and family offices. "This fund was built around one simple idea: the future of business and society will be defined by AI that works," said Afzal M. Tarar, Founder and Managing Partner of Quartus. "We invest in growth-stage AI and technology ventures and scale them into market leaders of the future that drive innovation, performance and impact." While fundraising, the Fund has deployed capital into a curated portfolio of 9 AI and technology ventures across sectors including healthcare, education, security and logistics. The Fund is benchmarked by Cambridge Associates and has been in the top quartile for net IRR and TVPI for most of the past 2 plus years. With the Fund's final closing, the firm is turning its attention to deploying the remaining capital and harvesting the Fund. About Quartus Capital PartnersQuartus Capital Partners LLC is an AI and technology investment firm with partner presence in New York City, Miami, Silicon Valley and Asia. The firm is led by AI pioneers, technologists, and seasoned operators. It invests in growth-stage ventures and scales them into market leaders that drive innovation, performance, and impact. Media Contact:Afzal M. TararFounder and Managing Partnerafzal@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
Invenra Welcomes Dr. Alan J. Korman to Its Scientific Advisory Board
MADISON, Wis., July 14, 2025--(BUSINESS WIRE)--Invenra, a biotechnology company specializing in next-generation multispecific antibody discovery and development, is pleased to announce the appointment of Dr. Alan J. Korman, PhD, FAIO, to its Scientific Advisory Board (SAB). Dr. Korman brings a wealth of experience in immuno-oncology, having played a pivotal role in the development of groundbreaking cancer immunotherapies. Dr. Korman is currently CSO and a member of the Board of Directors of Bluesphere Bio, a clinical stage biotech company in Pittsburgh, PA. Most recently, he served as Senior Vice President of Human Immunology at Vir Biotechnology. Prior to that, he served as Vice President for Immuno-Oncology Discovery at Bristol-Myers Squibb (BMS), where he led the development of biologics for tumor immunotherapy. During his tenure at BMS and Medarex, Dr. Korman contributed to the development of three approved oncology drugs: ipilimumab (anti-CTLA-4), nivolumab (anti-PD-1), and relatlimab (anti-LAG-3), as well as their combination, pioneering the use of immune checkpoint blockade in cancer therapy. Dr. Korman earned his PhD in Cellular and Developmental Biology from Harvard University and was a Whitehead Fellow at the Whitehead Institute at the Massachusetts Institute of Technology. He also served as a staff scientist at the Institut Pasteur before transitioning to the biotechnology sector. In addition to his new role on Invenra's SAB, Dr. Korman is also the founder of Spice Biotechnologies, a company focused on developing next-generation checkpoint therapeutics. "We are thrilled to welcome Dr. Korman to our Scientific Advisory Board," said Dr. Roland Green, Co-Founder, CEO, and Chairman of Invenra. "His extensive experience in developing transformative immunotherapies aligns perfectly with Invenra's mission to collaborate with and support biotech and pharmaceutical companies of all sizes globally. We look forward to his valuable insights and contributions as we continue to empower our partners to advance innovative therapeutics." Dr. Korman joins SAB members Dr. Paul Sondel and Dr. Jonathan Davis, whose knowledge and guidance have supported Invenra's research and development. Dr. Paul Sondel, MD, PhD, is the Reed and Carolee Walker Professor in Pediatric Oncology at the University of Wisconsin–Madison. With a distinguished career in cancer immunotherapy, Dr. Sondel has led lab, translational, and clinical research within the UW Carbone Cancer Center. His work has significantly advanced the understanding and application of immunotherapeutic strategies, including the development of FDA-approved treatments for high-risk neuroblastoma. Dr. Jonathan Davis, PhD, brings over 20 years of experience in the life sciences industry, focusing on protein and antibody engineering, as well as bispecific and multispecific antibody platform development. Prior to joining the Invenra SAB, Dr. Davis was Vice President of Innovation and Strategy for Invenra where he focused on optimization of the B-Body Platform, the development of antibody libraries, and refinements to screening methodology and throughput. Prior to Invenra, he was a Principal Scientist at Bristol-Myers Squibb, where he contributed to biologic drug design, including the development of a trispecific HIV biotherapeutic. Prior to that, he worked at EMD Serono, where he developed a variety of novel biologic drug platforms. "The collective expertise of Drs. Korman, Sondel, and Davis positions Invenra as a key collaborator and service provider, driving the discovery and development of multispecific antibody-based therapeutics in partnership with biotech and pharmaceutical companies worldwide," added Dr. Green. "Their combined knowledge and experience will be invaluable as we continue to support our partners in bringing novel treatments to patients in need." For more information about Invenra and its Scientific Advisory Board, please visit About Invenra Invenra Inc. is a biotechnology company specializing in next-generation multispecific antibody discovery and development. Its proprietary B-Body® platform enables the rapid generation of highly developable bispecifics and now supports both Rapid Bispecific Discovery Services—delivering lead panels in as little as four months—and B-Body Express™, which quickly produces high-quality bispecifics from partner-provided sequences. Invenra's newly launched T-Body™ platform expands these capabilities for efficient expression, correct chain pairing, and robust assembly of trispecific constructs. Invenra partners globally with pharmaceutical and biotech companies to accelerate therapeutic antibody programs from discovery through preclinical development. View source version on Contacts Invenra Inc.5510 Element Way, Suite 400Madison, WI 53719Phone: 608.441.8319Email: info@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
